Preclinical Targeted α- and β

HER2 brain metastasis single-domain antibody fragment targeted radionuclide therapy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
21 Apr 2020
Historique:
received: 06 03 2020
revised: 13 04 2020
accepted: 16 04 2020
entrez: 25 4 2020
pubmed: 25 4 2020
medline: 25 4 2020
Statut: epublish

Résumé

HER2-targeted therapies have drastically improved the outcome for breast cancer patients. However, when metastasis to the brain is involved, current strategies fail to hold up to the same promise. Camelid single-domain antibody-fragments (sdAbs) have been demonstrated to possess favorable properties for detecting and treating cancerous lesions in vivo using different radiolabeling methods. Here we evaluate the anti-HER2 sdAb 2Rs15d, coupled to diagnostic γ- and therapeutic α- and β

Identifiants

pubmed: 32326199
pii: cancers12041017
doi: 10.3390/cancers12041017
pmc: PMC7226418
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Wetenschappelijk Fonds Willy Gepts
ID : N/A
Organisme : Fonds Wetenschappelijk Onderzoek
ID : N/A

Références

J Control Release. 2016 Dec 10;243:1-10
pubmed: 27671875
J Cereb Blood Flow Metab. 2014 May;34(5):820-6
pubmed: 24517973
J Nucl Med. 2018 Aug;59(8):1225-1233
pubmed: 29572254
Mol Cancer Ther. 2017 Oct;16(10):2191-2200
pubmed: 28619756
Antibodies (Basel). 2019 Mar 18;8(1):
pubmed: 31544831
Breast Cancer Res Treat. 2018 Jun;169(3):523-530
pubmed: 29442264
Breast Cancer Res. 2015 Nov 17;17:140
pubmed: 26578067
Breast Cancer Res. 2014 Mar 05;16(2):209
pubmed: 24887180
J Nucl Med. 2016 Jan;57(1):27-33
pubmed: 26449837
Ann Oncol. 2001;12 Suppl 1:S35-41
pubmed: 11521720
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2106-19
pubmed: 25070685
Cancer Res. 2007 May 1;67(9):4190-8
pubmed: 17483330
Oncotarget. 2017 Jul 26;8(48):83734-83744
pubmed: 29137378
Pharmaceutics. 2019 Aug 01;11(8):
pubmed: 31374991
J Clin Oncol. 2006 Dec 20;24(36):5658-63
pubmed: 17102066
J Gene Med. 2003 Aug;5(8):654-67
pubmed: 12898635
J Neurooncol. 2016 May;127(3):407-14
pubmed: 26909695
Nucl Med Biol. 2009 Aug;36(6):659-69
pubmed: 19647172
FASEB J. 2011 Jul;25(7):2433-46
pubmed: 21478264
Nanomedicine (Lond). 2017 Jul;12(13):1533-1546
pubmed: 28621578
Ann Oncol. 2013 Jun;24(6):1526-33
pubmed: 23463626
J Control Release. 2020 Jan 10;317:34-42
pubmed: 31734445
Int J Cancer. 1991 Nov 11;49(5):650-5
pubmed: 1682277
Theranostics. 2014 Apr 25;4(7):708-20
pubmed: 24883121
Clin Cancer Res. 2017 Nov 1;23(21):6616-6628
pubmed: 28751451
Clin Cancer Res. 2009 Feb 15;15(4):1452-9
pubmed: 19228746
Clin Pharmacol Ther. 2010 May;87(5):586-92
pubmed: 20357763
Expert Opin Biol Ther. 2016 Aug;16(8):1035-47
pubmed: 27145158
J Nucl Med. 2014 Apr;55(4):650-6
pubmed: 24578241
Mol Cancer Ther. 2017 Dec;16(12):2828-2839
pubmed: 29054987
J Nucl Med. 2017 Oct;58(10):1624-1631
pubmed: 28408529
Mol Pharm. 2018 Apr 2;15(4):1457-1466
pubmed: 29502411
J Clin Oncol. 2002 Feb 1;20(3):719-26
pubmed: 11821453
PLoS One. 2012;7(6):e38284
pubmed: 22675537
Data Brief. 2016 Jan 06;6:542-9
pubmed: 26904717
Breast Cancer Res Treat. 2020 May;181(1):115-125
pubmed: 32193802
Anticancer Res. 2020 Mar;40(3):1759-1770
pubmed: 32132085
J Virol. 2013 Oct;87(20):11304-8
pubmed: 23864630
Clin Cancer Res. 2007 Mar 15;13(6):1648-55
pubmed: 17363517
BMC Biol. 2017 Jul 3;15(1):57
pubmed: 28673288
Eur J Nucl Med Mol Imaging. 2008 May;35(5):999-1007
pubmed: 18180921
Lancet Oncol. 2013 Mar;14(3):244-8
pubmed: 23414588
Mol Imaging. 2003 Jul;2(3):131-7
pubmed: 14649056
Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1756-1757
pubmed: 31115638
Mol Imaging Biol. 2017 Dec;19(6):867-877
pubmed: 28409338
J Neuroimmunol. 2014 Jul 15;272(1-2):76-85
pubmed: 24864011
Leukemia. 2014 Feb;28(2):444-7
pubmed: 24166214
Mol Pharm. 2019 Aug 5;16(8):3524-3533
pubmed: 31268724
EJNMMI Res. 2018 Nov 29;8(1):103
pubmed: 30498938
Molecules. 2020 Feb 25;25(5):
pubmed: 32106568
Nucl Med Biol. 2018 Jan;56:10-20
pubmed: 29031230
NPJ Parkinsons Dis. 2018 Aug 22;4:25
pubmed: 30155513
J Nucl Med. 2010 Jun;51(6):892-7
pubmed: 20484419
J Nucl Med. 2018 Jun;59(6):900-906
pubmed: 29146695
N Engl J Med. 2005 Oct 20;353(16):1673-84
pubmed: 16236738
Clin Cancer Res. 2008 Feb 1;14(3):875-82
pubmed: 18245551

Auteurs

Janik Puttemans (J)

In vivo Cellular and Molecular Imaging laboratory, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

Yana Dekempeneer (Y)

In vivo Cellular and Molecular Imaging laboratory, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

Jos L Eersels (JL)

In vivo Cellular and Molecular Imaging laboratory, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

Heleen Hanssens (H)

In vivo Cellular and Molecular Imaging laboratory, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

Pieterjan Debie (P)

In vivo Cellular and Molecular Imaging laboratory, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

Marleen Keyaerts (M)

In vivo Cellular and Molecular Imaging laboratory, Vrije Universiteit Brussel, 1090 Brussels, Belgium.
Nuclear Medicine Department, UZ Brussel, 1090 Brussels, Belgium.

Albert D Windhorst (AD)

Amsterdam UMC (Universitair Medische Centra), Department of Radiology & Nuclear Medicine, Cancer Center Amsterdam, VU University, 1081 HV Amsterdam, The Netherlands.

Frank van der Aa (F)

Amsterdam UMC (Universitair Medische Centra), Department of Radiology & Nuclear Medicine, Cancer Center Amsterdam, VU University, 1081 HV Amsterdam, The Netherlands.

Quentin Lecocq (Q)

Laboratory for Molecular and Cellular Therapy, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

Karine Breckpot (K)

Laboratory for Molecular and Cellular Therapy, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

Alfred Morgenstern (A)

European Commission, Joint Research Centre, Department for Nuclear Safety and Security, P.O. Box 2340, 76125 Karlsruhe, Germany.

Frank Bruchertseifer (F)

European Commission, Joint Research Centre, Department for Nuclear Safety and Security, P.O. Box 2340, 76125 Karlsruhe, Germany.

Tony Lahoutte (T)

In vivo Cellular and Molecular Imaging laboratory, Vrije Universiteit Brussel, 1090 Brussels, Belgium.
Nuclear Medicine Department, UZ Brussel, 1090 Brussels, Belgium.

Nick Devoogdt (N)

In vivo Cellular and Molecular Imaging laboratory, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

Matthias D'Huyvetter (M)

In vivo Cellular and Molecular Imaging laboratory, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

Classifications MeSH